ELMD Electromed, Inc. Insider Trading

Director Kathleen Skarvan sold 40,000 shares (40.0K) for $1,419,358.25 on 2026-05-15, reducing holdings by 52.9%

Kathleen Skarvan executed 4 separate sales totaling 40,000 shares for $1,419,358.25 at prices ranging from $34.36 to $37.33, reducing her holdings from 75,622 shares to 35,622 shares. Her prior 5 sales at ELMD all showed negative 90-day returns, with outcomes of -24.9%, -24.6%, -39.0%, -39.2%, and -40.9%, and 5 of 5 prior sells were well-timed at the 90-day mark. The current stock price of $38.37 sits at -0.9% from the 52-week high of $38.71, after appreciating 47.2% over the past 30 days and 54.7% over 90 days. The substantial reduction in her equity stake, combined with the historical pattern at this ticker and the recent sharp price appreciation, warrants attention from investors monitoring director-level activity.

Director Summers Andrew sold entire 65.7K share stake (100% of holdings) for $1.6M across 5 trades at blended avg $24.32

Summers Andrew completely liquidated his entire 65,714-share position in Electromed through 5 separate sales totaling $1,598,453.61 on September 10–11, 2025, at prices ranging from $23.68 to $26.62. His prior trade history at this ticker shows a perfect 5-of-5 timing pattern: all five prior sells at ELMD were well-timed, with 90-day post-sale returns of -12.2% to -14.7%, indicating consistent execution before declines. His cross-ticker track record across 20 prior sells shows a 100.00% well-timed rate, though with a 90-day average return of -18.9%, suggesting his sells have historically preceded material pullbacks. The complete exit from a profitable position (transaction prices at $24.32 vs current price $23.88, and the stock is -32.6% from its 52-week high) combined with the director's demonstrated pattern of selling before subsequent weakness warrants close monitoring of company fundamentals and forward-looking disclosure.

Director Andrew Summers sold 111,475 shares (111.5K) at ELMD for $3,120,226.23, reducing holdings by 62.9% in 9 transactions Feb 20-24.

Andrew Summers, a Director at Electromed, Inc., executed 9 separate sales totaling 111,475 shares for $3,120,226.23 across February 20–24, 2025, at prices ranging from $27.30 to $29.81 (blended average $27.99). This represents a substantial reduction in his ownership stake, from 177,189 shares to 65,714 shares post-transaction, a net decrease of 62.9% of his pre-transaction holdings. The stock is currently trading at $26.97, down 19.5% over 30 days and down 23.9% from its 52-week high of $35.43, meaning Summers sold above the current price. His prior five trades at ELMD (all sells on 2024-12-05) averaged 30-day gains of 4.4–9.3%, suggesting consistent favorable near-term exit timing at this ticker, though 90-day outcomes remain unmeasurable for those transactions. The multi-transaction structure and substantial volume sold warrant careful review of whether this signals a major shift in director positioning or reflects portfolio adjustment against broader market headwinds.

Director Skarvan Kathleen sold 76,583 shares for $2,334,281.45 in 5 transactions, reducing holdings by -70.1%

Kathleen Skarvan, a director at Electromed, executed 5 separate sales totaling 76,583 shares (76.6K shares) for $2,334,281.45 ($2.3M) across two trading days at a blended average price of $30.48, reducing her stake from 109,205 shares (109.2K shares) to 32,622 shares (32.6K shares). This represents a substantial -70.1% reduction in holdings. The timing context is mixed: the stock has declined -17.1% from its 52-week high of $35.43 and is down -13.6% over the past 30 days, yet her prior three sales at ELMD (all in November 2024) failed to precede declines—each was followed by positive 90-day returns of +14.2%, +14.0%, and +13.2% respectively, indicating a 0.00% well-timed rate on same-ticker history. The company shows moderate fundamentals with quarterly revenue of $16,255,000.00, net income of $1,968,000.00, and annual revenue growth of +13.8%, but trades at a elevated P/E of 37.16. The substantial size and one-time nature of this liquidation—disposing of over two-thirds of her position—warrants observation for any strategic restructuring or personal circumstance signaling by the director.

Director Andrew Summers sold 37,404 shares (~20.3% of holdings) at ELMD for $1,052,752.18 across 6 separate transactions on 2024-12-05.

Andrew Summers, Director of Electromed, Inc., executed 6 separate sales totaling 37,404 shares for $1,052,752.18 on 2024-12-05, reducing his holdings from 184,231 to 146,827 shares. The sales occurred at prices ranging from $28.09 to $29.41, with a blended average of $28.15, near the current market price of $28.71. The reduction of 20.3% of pre-transaction holdings in a single day represents a material liquidation; combined with his pattern of 5 consecutive sell transactions at ELMD on 2024-12-02 through 2024-12-04 (outcomes not yet measurable), this suggests a deliberate multi-day divestiture. ELMD trades at a P/E of 37.78 with recent strong momentum (+66.4% over 90 days, +19.4% over 30 days), yet the director has chosen to exit a significant portion rather than maintain exposure during this uptrend.

Director Andrew Summers sells 65,630 shares of ELMD for $1,976,605.87 across 7 trades; reduces stake by 28.4%

Andrew Summers, a director at Electromed, executed 7 separate sales totaling 65,630 shares (65.6K shares) for $1,976,605.87 ($2.0M) at a blended average price of $30.12 across December 2–4, 2024. This represents a reduction of 28.4% of his pre-transaction holdings from 231,385 shares to 165,755 shares post-transaction. The sales occurred while the stock trades at $29.80 current price, near the 52-week high of $31.06 (-4.1%), and after significant recent momentum: the stock has risen 30.9% in the past 30 days and 74.2% over 90 days. His prior buy at ELMD in December 2023 achieved a 90-day return of +61.1%, indicating his historical trades at this ticker have been well-positioned. The scale of this multi-day liquidation—selling nearly a third of his holdings during a period of strong upward price action—warrants attention to whether this reflects changed circumstances or opportunistic capital redeployment.

Director Kathleen Skarvan sold 150,000 shares (83.8% of holdings) for $4.2M across 3 transactions on 2024-11-18/19.

Kathleen Skarvan, a Director at Electromed, executed 3 separate sales totaling 150,000 shares for $4,201,350.46 at blended average price of $28.01 on November 18–19, 2024, reducing her holdings from 178,989 shares to 28,989 shares (−83.8% of pre-transaction holdings). The stock currently trades at $29.21, near its 52-week high of $29.21, and has surged +28.1% over the past 30 days and +88.3% over 90 days—gains realized after her sales completed. Her cross-ticker track record shows a 100% win rate on 90-day returns averaging +17.2% after her prior buy, indicating her historical trades have captured positive momentum; however, this sell occurred as the stock was approaching peak pricing in a strong uptrend, meaning she forfeited subsequent gains. The company demonstrates solid fundamentals (13.8% annual revenue growth, $14.7M latest quarterly revenue, $1.5M net income) and a market cap of $247.1M, but the P/E of 38.43 reflects elevated valuation relative to earnings.